Dexmedetomidine Transdermal Patch for Non-Sedative Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing pain, particularly chronic and neuropathic pain, often rely on sedative medications that can impair consciousness and responsiveness, and there is a need for a non-sedative transdermal delivery system that effectively administers dexmedetomidine to provide pain relief without causing sedation.
Innovation Solution
A transdermal delivery device comprising dexmedetomidine, a solubility enhancer, and an acrylate-pressure sensitive adhesive with pendant hydroxyl groups, designed to passively deliver a therapeutically effective amount of dexmedetomidine, allowing for pain management in non-sedated subjects while maintaining alertness and responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If sedative medications are administered to manage pain, then pain relief is achieved, but consciousness and responsiveness are impaired
Solution Approach 1:
The patent changes the key parameter of dexmedetomidine dosage and delivery method to achieve pain relief at sub-sedative levels. By using transdermal delivery with controlled flux rates (0.005-5 μg/cm²/hr) and specific formulation parameters (solubility enhancers, adhesive types), the system delivers sufficient drug to manage pain while maintaining the subject in a non-sedated state with preserved consciousness and responsiveness
Solution Approach 2:
The patent introduces transdermal delivery system components as intermediaries between the dexmedetomidine drug and the subject's systemic circulation. These include solubility enhancers (e.g., oleic acid, lauryl lactate), adhesives (acrylate pressure-sensitive adhesives with hydroxyl groups), and formulation excipients that mediate the drug's delivery to achieve therapeutic pain relief while controlling the rate and extent of absorption to prevent sedation
2Quantity of substance
If parenteral or oral dexmedetomidine is administered, then sedation and analgesia are achieved, but close supervision by health care professionals is required
Solution Approach 1:
The patent creates a self-administerable transdermal delivery system that does not require close medical supervision. The formulation is designed to automatically control drug release through the skin at safe, sub-sedative rates, allowing subjects to manage their own pain without requiring continuous monitoring by health care professionals, thus enabling self-service administration
Solution Approach 2:
The transdermal delivery device is designed as a disposable, single-use system that is applied to the skin and removed after a predetermined period (e.g., 24 hours). This eliminates the need for repeated administrations and continuous supervision, making the treatment simpler and more accessible while maintaining safety through controlled, limited-duration drug delivery
3Object-generated harmful factors
If transdermal delivery system is designed, then non-sedative pain relief is achieved, but formulation complexity increases
Solution Approach 1:
The patent employs composite formulation materials to achieve non-sedative pain relief through transdermal delivery. The system combines dexmedetomidine with solubility enhancers (e.g., oleic acid, lauryl lactate, polyisobutylene), specific adhesives (acrylate pressure-sensitive adhesives with pendant hydroxyl groups), and other excipients in a laminated composite structure. This composite approach enables controlled, sub-sedative drug delivery while managing the complexity through standardized material combinations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively manages pain by delivering a non-sedative amount of dexmedetomidine transdermally, providing pain relief without impairing consciousness or responsiveness, as evidenced by maintained Ramsay scores indicating alertness and cooperation during administration.
Implementation Method 1
the dexmedetomidine composition is formulated to passively deliver a therapeutically effective amount of dexmedetomidine
Implementation Method 2
a solubility enhancer
Data Source
Figure 1
Figure 2(A)~2(C)
Figure 3
AI summary
Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject experiencing pain. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. Also provided are transdermal delivery devices configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.